STABILIZED ENZYME COMPOSITIONS

A medical device includes a base material having an immobilized enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. An enzyme is immobilized on the base material. The enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa). 1. A medical device comprising:a base material including an immobilized enzyme covalently bound to the base material and dextran sulfate, the medical device being for vascular implantation in a patient, the dextran sulfate having a molecular weight that is about 8 kilodaltons (kDa) to stabilize the enzyme when in contact with blood of the patient.2. The medical device according to claim 1 , wherein the enzyme includes at least one of: a urokinase-type plasminogen activator (uPA);', 'a tissue plasminogen activator (tPA); and', 'a streptokinase; and, 'a blood clot digestive enzyme including one or more of a protease;', 'an aminopeptidase;', 'a collagenase;', 'a matrix metalloproteinase;', 'a metalloendopeptidase;', 'a serine endopeptidase;', 'a hydrolase;', 'a glucuronidase;', 'a hyaluronoglucosaminidase;', 'a heparanase;', 'a cathepsin;', 'a hyaluronidase; and', 'a matriptase., 'an extracellular matrix digestive enzyme including one or more of3. The medical device according to claim 1 , further comprising:a combination of two or more antimicrobial agents impregnating the base material.4. The medical device according to claim 3 , wherein the combination of two or more antimicrobial agents includes at least two of: a chlorhexidine base; and', 'an alexidine;, 'a pharmaceutically acceptable salt of a bis-biguanide including at least one ofa guanide including polyhexamethylene biguanide (PHMB);a cationic selective antimicrobial (CSA); anda ceragenin.5. The medical device according to claim 1 , further comprising:an antimicrobial agent impregnating the base material.6. The medical device according to ...

Tubular woven fabric

A tubular woven fabric is useful as a transport hose for a fluid or a powder, as a protective hose for linear bodies such as wires, cables and conduits, as a tubular filter, or as a base material of a vascular prosthesis. The tubular woven fabric includes warp yarns and weft yarns interwoven with each other, the tubular woven fabric having an outer diameter with a variation of within 10% along the warp direction and satisfying the formula: ( L 2− L 1)/ L 1≤0.1.

MEDICAL SUPPLY

A medical material has a compound firmly immobilized on the surface thereof, which compound is capable of inhibiting both of the blood coagulation reactions in a primary hemostasis stage in which platelets are involved and in a coagulation thrombus formation stage in which blood coagulation factors are involved in a state retaining the anticoagulant activity. The present invention provides a medical material having a hydrophilic polymer compound immobilized on the surface thereof, in which a compound and a copolymer of monomers selected from the group consisting of ethylene glycol, vinyl acetate, vinyl pyrrolidone, propylene glycol, vinyl alcohol and siloxane are bound. 2. The medical material according to claim 1 , wherein said copolymer is a polyether-modified silicone.3. The medical material according to claim 1 , wherein said compound of the formula (I) is (2R claim 1 ,4R)-4-methyl-1-(2S)-2-{[(3RS)-3-methyl-1 claim 1 ,2 claim 1 ,3 claim 1 ,4-tetrahydroquinolin-8-yl]sulfonyl} amino-5-guanidinopentanoyl)piperidine-2-carboxylic acid.4. The medical material according to comprising any selected from the group consisting of polyester claim 1 , polyurethane claim 1 , polystyrene claim 1 , polymethyl methacrylate claim 1 , polyvinyl chloride claim 1 , polytetrafluoroethylene and polysulfone as a material.5. The medical material according to claim 1 , which is a hollow fiber membrane.6. A module for hemocatharsis filled with said medical material according to .7. The medical material according to claim 2 , wherein said compound of formula (I) is (2R claim 2 ,4R)-4-methyl-1-(2S)-2-{[(3RS)-3-methyl-1 claim 2 ,2 claim 2 ,3 claim 2 ,4-tetrahydroquinolin-8-yl]sulfonyl} amino-5-guanidinopentanoyl)piperidine-2-carboxylic acid.8. The medical material according to comprising any selected from the group consisting of polyester claim 2 , polyurethane claim 2 , polystyrene claim 2 , polymethyl methacrylate claim 2 , polyvinyl chloride claim 2 , polytetrafluoroethylene and ...

APPARATUS FOR THE EXTRACORPOREAL TREATMENT OF BLOOD

An apparatus for the extracorporeal treatment of blood comprising an extracorporeal blood circuit (), a pump () configured to provide fluid displacement within the extracorporeal blood circuit, and a reaction chamber () connected to the extracorporeal blood circuit and configured to receive blood or plasma from the circuit and treat the blood or plasma. The reaction chamber comprises a protease enzyme immobilized to a support, in which the protease enzyme is specific for, and capable of irreversibly cleaving, a human C5a present in the blood or plasma, wherein the abundance of the human C5a in the treated blood or plasma is less than that in the untreated blood or plasma. The apparatus finds utility in the extracorporeal treatment of blood from patients with inflammatory conditions, especially auto-immune disease and sepsis. 1. A method for the extracorporeal treatment of blood , the method comprising removing blood or a blood fraction from a patient and reacting the blood or blood fraction with a protease enzyme that is specific for and capable of irreversibly cleaving functional C5a , thereby reducing an abundance of functional C5a in the blood or blood fraction , wherein the protease enzyme is immobilised to a support.23. The method of claim 1 , wherein the protease enzyme is a recombinant bacterial C5a protease comprising SEQ ID NO. claim 1 , or a functional variant thereof having at least 90% sequence identity with SEQ ID NO: 3.3. The method of claim 2 , wherein the functional variant of SEQ ID NO: 3 is SEQ ID NO: 4 or SEQ ID NO: 5.4. The method of claim 1 , wherein the reacting step is carried out with an apparatus comprising:an extracorporeal blood circuit;a pump configured to provide fluid displacement with the extracorporeal blood circuit; anda reaction chamber connected to the extracorporeal blood circuit, the reaction chamber configured to receive the blood or blood fraction from the extracorporeal blood circuit and to treat the blood or blood fraction, ...

USES OF CYANOBACTERIUM EXTRACELLULAR POLYMER, COMPOSITIONS, COATED SURFACES OR ARTICLES

The present disclosure relates to a coating with anti-adhesive properties (in order to repel or prevent bacterial or platelet adhesion) based on a naturally produced polymer. This polymer that has been extensively characterized and is produced by a marine bacterium—sp. CCY 0110, at optimized production conditions to obtain increased amounts of polymer. Importantly, this strain is among the highly efficient polymer producers, secreting the polymer directly to the media, allowing the easy recovery of polymer with few purification steps, being a cost-effective product. The coating can be applied to medical devices or medical implants to prevent biofilm mediated infections thereof. 1Cyanothece. A composition comprising a polymer released from sp. CCY 0110 for use in the preventive treatment of a biofilm-mediated infection of medical devices.2S. epidermidisS. aureus.. The composition according to claim 1 , wherein the biofilm-mediated infection of medical devices is caused by or3S. epidermidis.. The composition according to claim 2 , wherein the biofilm-mediated infection of medical devices is caused by4S. epidermidis. The composition according to claim 3 , wherein the biofilm-mediated infection of medical devices is caused by a highly adhesive strain in the presence of human plasma proteins.5. The composition according to claim 1 , wherein said composition is further used for preventing platelet adhesion to the composition and activation of said platelets.6. A method for coating a medical device comprising the step of{'i': 'Cyanothece', 'applying a polymer released from sp. CCY 0110, for use in preventive treatment of a biofilm-mediated infection.'}7S. epidermidisS. aureus.. The method according to claim 6 , wherein the biofilm-mediated infection is caused by or8S. epidermidis. The method according to claim 7 , wherein the biofilm-mediated infection is caused by a highly adhesive strain in the presence of human plasma proteins.9. The method according to claim 6 , ...

MEDICAL DEVICES WITH REDUCED THROMBOGENICITY

A plasma-activated coating (PAC) process covalently binds enzymes in their bioactive state, has low thrombogenicity and can be robustly applied to medical devices, resisting delamination when deployed in vivo. Applying this process to attachment of proteins such as enzymes that inhibit thrombosis and anticoagulants such as heparin or heparin fragments, one can produce medical devices and other materials for use in vascular applications having a number of benefits including covalent attachment, not requiring intermediate linkers or chemistry; substrate independent works on polymers, metals, ceramics, 3D shapes like stents, valves, etc.; bioactivity is retained; surface may retain greater bioactivity over time in vivo; Simultaneously supports endothelialisation; can be stored for long periods, following freeze drying, and retains effectiveness when rehydrated and; surface is able to bind many fibrinolytic enzymes such as streptokinase, urokinase, tPA, plasmin). 1. A vascular medical device comprising a surface consisting of a plasma polymerized biocompatible polyhexane or polyacetyiene having nitrogen incorporated therein on a metallic , ceramic , carbon or polymeric substrate of the device which contacts blood ,wherein the substrate is coated with a plasma-activated mediator;and wherein the thrombogenicity of the substrate is reduced by the immobilization of an anti-thrombogenic, anti-platelet or anti-coagulant protein to the mediator.2. The device of wherein the protein is an enzyme.3. The device of wherein the enzyme is fibrinolytic.4. The device of wherein the enzyme is selected from the group consisting of plasmin claim 3 , tissue plasminogen activator (tPA) including alteplase claim 3 , reteplase claim 3 , tenecteplase and desmoteplase claim 3 , streptokinase claim 3 , urokinase claim 3 , and plasminogen.5. The device of comprising anti-thrombogenic agent selected from the group consisting of direct thrombin inhibitors such as bivalirudin claim 1 , and heparins ...

CLOT ADHESION PREVENTING AGENT AND BLOOD COLLECTION CONTAINER

Provided is a clot adhesion preventing agent capable of suppressing adhesion of clot to the inner wall surface of a blood collection container. The clot adhesion preventing agent according to the present invention includes a polyether compound or a silicone oil, and an amino acid.

Catheter Locking Solution Having Antimicrobial and Anticoagulation Properties

The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine. 1. A catheter locking solution comprising:a local anesthetic comprising at least one of dibucaine and tetracaine having anticoagulant and antimicrobial activity to reduce microbial growth and coagulation in an implanted catheter; anda viscosifying agent.2. The catheter locking solution of claim 1 , wherein the local anesthetic comprises one or more of an amino amide claim 1 , an amino ester claim 1 , an aminoacylanilide claim 1 , an aminoalkyl benzoate claim 1 , an amino carbonate claim 1 , an N-phenylamidine compound claim 1 , an N-aminoalkyl amid claim 1 , an aminoketone claim 1 , and combinations thereof.3. The catheter locking solution of claim 1 , wherein the local anesthetic further comprises one or more of bupivacaine claim 1 , ropivacaine claim 1 , etidocaine claim 1 , lidocaine claim 1 , prilocaine claim 1 , procaine claim 1 , novocaine claim 1 , choloroprocaine claim 1 , propoxycaine claim 1 , chlorocaine claim 1 , mepivacaine claim 1 , xylocaine claim 1 , benzocaine claim 1 , chloroprocaine claim 1 , cyclomethycaine claim 1 , dimethocaine claim 1 , popoxycaine claim 1 , proparacaine claim 1 , articaine claim 1 , carticaine claim 1 , levobupivacaine claim 1 , piperocaine claim 1 , trimecaine claim 1 , hexylcaine claim 1 , benoxinate claim 1 , butucaine claim 1 , diperodon claim 1 , phenacaine claim 1 , falicaine claim 1 , dyclonine claim 1 , pramoxine claim 1 , dimethisoquien claim 1 , and combinations thereof.4. The catheter locking ...

Method for immobilizing heparin and no-generating catalyst and cardiovascular device having surface modified using the same

The present disclosure relates to a method for immobilizing heparin and a NO-generating catalyst and a cardiovascular device having a surface modified using the same, and more particularly, to a method of co-immobilizing a heparin-phenol derivative and copper nanoparticles as a NO-generating catalyst on the surface of a material by a polyphenol oxidase-mediated reaction, a material having a surface with heparin and a NO-generating catalyst co-immobilized thereon by using the method, and a cardiovascular device including the material. It has been confirmed that a surface having heparin and the NO-generating catalyst co-immobilized thereon by the method of the present disclosure has high in vivo stability, continuously generates NO, and also promotes the proliferation of endothelial cells while significantly inhibiting the adhesion and activation of platelets and smooth muscle cells. Thus, the method may be advantageously applied to cardiovascular devices for inhibiting thrombosis and restenosis.

APPARATUS FOR THE EXTRACORPOREAL TREATMENT OF BLOOD

An apparatus for the extracorporeal treatment of blood comprising an extracorporeal blood circuit (), a pump () configured to provide fluid displacement within the extracorporeal blood circuit, and a reaction chamber () connected to the extracorporeal blood circuit and configured to receive blood or plasma from the circuit and treat the blood or plasma. The reaction chamber comprises a protease enzyme immobilized to a support, in which the protease enzyme is specific for, and capable of irreversibly cleaving, a human C5a present in the blood or plasma, wherein the abundance of the human C5a in the treated blood or plasma is less than that in the untreated blood or plasma. The apparatus finds utility in the extracorporeal treatment of blood from patients with inflammatory conditions, especially auto-immune disease and sepsis. 1. A method for the extracorporeal treatment of blood , the method comprising removing blood or a blood fraction from a patient and reacting the blood or blood fraction with a protease enzyme that is specific for and capable of irreversibly cleaving functional C5a , thereby reducing an abundance of functional C5a in the blood or blood fraction , wherein the protease enzyme is immobilised to a support.2. The method of claim 1 , wherein the protease enzyme is a recombinant bacterial C5a protease comprising SEQ ID NO. 3 claim 1 , or a functional variant thereof having at least 90% sequence identity with SEQ ID NO: 3.3. The method of claim 2 , wherein the functional variant of SEQ ID NO: 3 is SEQ ID NO: 4 or SEQ ID NO: 5.5. The method of claim 4 , wherein the protease enzyme is a recombinant bacterial C5a protease comprising SEQ ID NO. 3 claim 4 , or a functional variant thereof having at least 90% sequence identity with SEQ ID NO: 3.6. The method of claim 5 , wherein the functional variant of SEQ ID NO: 3 is SEQ ID NO: 4 or SEQ ID NO: 5.7. The method of claim 4 , wherein the apparatus further comprises separating means adapted to separate the blood ...

CATHETER LOCK SOLUTION FORMULATIONS

A liquid excipient is added to a lock solution formulation containing a lower alcohol and an anti-coagulant, antibiotic, and/or anti-microbial, such as the ethanol and tri-sodium citrate lock solution formulation, to prevent citrate from crystallizing in catheters made from silicone. The locking solution could include a liquid excipient, such as glycerol, polysorbate-20, or polyethylene glycol (PEG)-400, along with a lower alcohol, such as ethanol, and an anti-coagulant, such as tri-sodium citrate, antibiotic, and/or anti-microbial. 1. A locking composition for a catheter comprising:at least one lower alcohol; at least one functional compound; and at least one excipient at a sufficient concentration to prevent occlusion of the catheter.2. The locking composition of claim 1 , wherein the at least one functional compound is at least one anti-coagulant.3. The locking composition of claim 1 , wherein the at least one functional compound is at least one anti-microbial.4. The locking composition of claim 1 , wherein the at least one functional compound is at least one antibiotic.5. The locking composition of claim 1 , wherein the at least one lower alcohol is present in the amount of about 30% by weight of the locking composition.6. The locking composition of claim 2 , wherein the at least one anti-coagulant compound is present in the amount of about 4% by weight of the locking composition.7. The locking composition of claim 1 , wherein the at least one excipient is present in the amount of at least about 0.5% by weight of the locking composition.8. The locking composition of claim 7 , wherein the at least one excipient is at least one liquid excipient.9. The locking composition of claim 1 , wherein the at least one liquid excipient is selected from PEG-100 claim 1 , PEG-200 claim 1 , PEG-300 claim 1 , Triton X-100 claim 1 , Polysorbate-80 claim 1 , Poloxomer 124 claim 1 , Macrogel 15 Hydroxy Stearate claim 1 , Cremophor EL claim 1 , and combinations thereof.10. The ...

ANTITHROMBOTIC COATING COMPOSITION AND ANTITHROMBOTIC COATING METHOD USING SAME

Disclosed is an antithrombotic coating composition and a coating method using the same. The composition is highly hydrophilic and biocompatible, thereby enabling a thin and flexible coating layer. The composition is suitably used for coating vascular catheters, stents, guide wires, and other invasive medical devices. 1. An antithrombotic coating composition comprising:a first coating solution comprising at least one selected from the group consisting of an acrylic compound and a polyurethane compound;a second coating solution comprising a polysaccharide and an antithrombotic substance; anda cross-linking agent.2. The antithrombotic coating composition of claim 1 , wherein the antithrombotic substance is at least one selected from the group consisting of heparin claim 1 , hirudin claim 1 , H-heparin claim 1 , HSI-heparin claim 1 , streptokinase claim 1 , neurokinase claim 1 , fucoidan claim 1 , and 2-methacryloyloxyethyl phosphorylcholine (MPC).3. The antithrombotic coating composition of claim 1 , wherein the first coating solution is to be bound to a substrate claim 1 , and the second coating solution is to be bound claim 1 , by the cross-linking agent claim 1 , to the first coating solution bound to the substrate.4. The antithrombotic coating composition of claim 1 , wherein the acrylic compound is an acrylate polymer.5. The antithrombotic coating composition of claim 1 , wherein the polyurethane compound is polyether polyurethane.6. The antithrombotic coating composition of claim 1 , wherein the polysaccharide is hyaluronic acid.7. The antithrombotic coating composition of claim 1 , wherein the cross-linking agent is a polyaziridine-based or polyisocyanate-based cross-linking agent.8. The antithrombotic coating composition of claim 1 , wherein the second coating solution further comprises polyether polyurethane.9. The antithrombotic coating composition of claim 8 , wherein the polysaccharide and the polyether polyurethane are present in a weight ratio of 10:0.5 ...

Coatings and biomedical implants formed from keratin biomaterials

Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof.

Compositions Comprising Oxidized Cellulose

The present invention provides compositions comprised of oxidized cellulose (OC) and glycerol, with the ratio of glycerol to OC being at least about 0.5:1 w/w glycerol:OC and/or with the viscosity of the composition being at least 10% higher than that of the glycerol and lower than about 2.6×10cP, with the total water content being less than about 8% w/w. Further provided is adhesion prevention powder comprised of OC having a carboxyl content of equal to below 18% characterized by high adhesion prevention potency. Uses of the compositions as hemostats or as adhesion prevention material, and methods for the preparation thereof are further provided herein. 1. A composition comprising oxidized cellulose (OC) and glycerol , wherein(i) the ratio of glycerol to OC is at least about 0.5:1 w/w glycerol:OC;(ii) the total water content is less than about 8% w/w; and(iii) the composition is in the form of a paste at one or more temperature values selected from the group consisting of 10° C., 15° C., 20° C., 25° C., 30° C., 35° C., 37° C., and 40° C.2. The composition of claim 1 , having a viscosity of at least about 10% higher than that of the glycerol at one or more temperature values selected from the group consisting of 10° C. claim 1 , 15° C. claim 1 , 20° C. claim 1 , 25° C. claim 1 , 30° C. claim 1 , 35° C. claim 1 , 37° C. claim 1 , and 40° C.3. The composition of claim 1 , having a resistance to penetration lower than about 20 N claim 1 , and optionally higher than about 1 N claim 1 , as measured in a tensile machine adjusted to monitor a probe having a 1.27 cm diameter at a speed of 30 mm/min from a defined preload of 0.1 N at 8 mm penetration at about room temperature.4. The composition of any one of claim 1 , wherein the ratio of glycerol to OC is between about 0.5:1 and about 6:1 w/w glycerol:OC claim 1 , and optionally claim 1 , wherein OC comprises oxidized regenerated cellulose (ORC).5. The composition of claim 1 , further comprising at least one biologically ...

Inhibition of Platelet Absorption

A cardiovascular graft is provided with highly reduced thrombogenicity. The cardiovascular graft is an electrospun non-woven mesh produced from supramolecular polymers with large diameter fibers. The cardiovascular graft can be implemented as a vascular graft into the human body to allow vascular bypass/reconstruction, or repeated venous access for dialysis treatment, as well as other disorders of small-diameter blood vessels. 1. A method of using a cardiovascular graft to reduce thrombogenic effects , comprising:having a cardiovascular graft designed as a tubular structure with an inner wall made out of a fibrous network of supramolecular compounds having hard-blocks covalently bonded with soft-blocks, wherein the hard-blocks comprise 2-ureido-4[1H]-pyrimidinone (UPy) compounds, wherein the fibrous network is a bioresorbable electrospun non-woven fibrous network with fibers having an average fiber diameter of 1-10 microns, and wherein the tubular structure has an inner diameter between 2-8 mm, and an inner wall thickness of 20-900 micrometers; andusing the cardiovascular graft to reduce thrombogenic effects upon implantation of the cardiovascular graft in a human body.2. The method as set forth in claim 1 , further comprises administering an an αβinhibitor in combination with the implantation of the cardiovascular graft.3. The method as set forth in claim 1 , wherein the inner wall has a thickness of at least 200 micrometers and has pores with an average pore size between 5 and 10 micrometers.4. The method as set forth in claim 1 , wherein the inner wall has pores with an average pore size between 5 and 8 micrometers and an average porosity ranging from 50 to 80%.5. The method as set forth in claim 1 , wherein the tubular structure has an inner diameter between 3-6 mm and a wall thickness of 200-800 microns.6. The method as set forth in claim 1 , wherein the tubular structure has an inner diameter between 4-8 mm and an inner wall thickness of 300-900 microns.7. The ...

TUBULAR WOVEN CONSTRUCT

A multi-layer tubular woven construct is useful as a hose that transports a fluid or a powder or protects linear bodies such as wires, cables and conduits, as a tubular filter, or as a base material of a vascular prosthesis. In particular, a tubular woven construct in a tubular configuration woven by interlacing warp and weft yarns contains at least in part an elastic fiber yarn having a filament fineness of 1.0 dtex or more, the weft yarn containing at least in part a microfiber yarn having a filament fineness of less than 1.0 dtex. 117-. (canceled)18. A tubular woven construct in a tubular configuration woven by interlacing warp and weft yarns , the warp yarn containing at least in part an elastic fiber yarn having a filament fineness of 1.0 dtex or more , the weft yarn containing at least in part a microfiber yarn having a filament fineness of less than 1.0 dtex.19. The tubular woven construct according to claim 18 , that satisfies formula: Cfa Подробнее

ANTI-THROMBOTIC MATERIAL

An antithrombogenic material includes: a coating material containing a skeletal structure composed of a polymer, a skeletal structure composed of 4-(aminomethyl)benzenecarboxyimidamide or benzene amidine, and a skeletal structure composed of methoxybenzenesulfonic acid amide; and a base material whose surface is coated with the coating material; wherein the coating material is covalently bound to the base material, and the peak abundance ratio of the carbonyl-derived component in the total component of the C1s peak as measured by X-ray photoelectron spectroscopy on the surface is not less than 1.0 atomic percent. 111.-. (canceled)12. An antithrombogenic material comprising:a coating material containing: a skeletal structure composed of a polymer containing, as a constituent monomer, a compound selected from the group consisting of ethylene glycol, propylene glycol, vinylpyrrolidone, vinyl alcohol, vinylcaprolactam, vinyl acetate, styrene, methyl methacrylate, hydroxyethyl methacrylate, and siloxane; a skeletal structure composed of 4-(aminomethyl)benzenecarboxyimidamide or benzene amidine; and a skeletal structure composed of methoxybenzenesulfonic acid amide; anda base material whose surface is coated with said coating material;whereinsaid coating material is covalently bound to said base material; anda peak abundance ratio of a carbonyl-derived component in a total component of the C1s peak as measured by X-ray photoelectron spectroscopy (XPS) on the surface is not less than 1.0 atomic percent.14. The antithrombogenic material according to claim 12 , wherein said coating material comprises at least one of a betaine compound claim 12 , cationic polymer claim 12 , anionic polymer claim 12 , and anionic compound claim 12 , and has an antithrombogenic action.15. The antithrombogenic material according to claim 13 , whereinsaid coating material comprises a betaine compound;each of said compound represented by Formula (I) and said betaine compound is covalently bound to ...

Apparatus for the extracorporeal treatment of blood

An apparatus for the extracorporeal treatment of blood comprising an extracorporeal blood circuit ( 2 ), a pump ( 6 ) configured to provide fluid displacement within the extracorporeal blood circuit, and a reaction chamber ( 8 ) connected to the extracorporeal blood circuit and configured to receive blood or plasma from the circuit and treat the blood or plasma. The reaction chamber comprises an protease enzyme immobilized to a support, in which the protease enzyme is specific for, and capable of irreversibly cleaving, a human C5a present in the blood or plasma, wherein the abundance of the human C5a in the treated blood or plasma is less than that in the untreated blood or plasma. The apparatus finds utility in the extracorporeal treatment of blood from patients with inflammatory conditions, especially auto-immune disease and sepsis.

BIODEGRADABLE, NON-THROMBOGENIC ELASTOMERIC POLYURETHANES

A method of forming an implantable article includes providing a biodegradable polymer including anti-thrombogenic groups along the length of the biodegradable polymer, biodegradable groups in the backbone of the biodegradable polymer and a plurality of functional groups adapted to react with reactive functional groups on a surface of the implantable article, and reacting at least a portion of the plurality of functional groups with the reactive functional groups on the surface of the implantable article. 1. A method of forming an implantable article , comprising: providing a biodegradable polymer comprising anti-thrombogenic groups along the length of the biodegradable polymer , biodegradable groups in the backbone of the biodegradable polymer and a plurality of functional groups adapted to react with reactive functional groups on a surface of the implantable article; and reacting at least a portion of the plurality of functional groups with the reactive functional groups on the surface of the implantable article.2. The method of wherein the biodegradable groups include at least one hydrolytically labile bond.3. The method of wherein the biodegradable groups comprise at least one of ester groups claim 1 , anyhydride groups claim 1 , amide groups claim 1 , carbonate groups claim 1 , an orthoester groups claim 1 , or thioether-ester groups.4. The method of wherein the biodegradable groups comprise ester groups.5. The method of wherein the anti-thrombogenic groups comprise zwitterionic groups.6. The method of wherein the anti-thrombogenic groups comprise at least one of a phosphorylcholine group claim 5 , a derivative of a phosphorylcholine group claim 5 , a sulfobetaine group claim 5 , a derivative of a sulfobetaine group claim 5 , a carboxybetaine group claim 5 , or a derivative of a carboxybetaine group.7. The method of wherein the biodegradable polymer is a thermoplastic elastomer.8. The method of wherein the biodegradable polymer comprises at least one of urethane ...

Implantable medical products, a process for the preparation thereof, and use thereof

Implantable medical product, comprising a basic body and an imidazole derivative in the form of its free base; wherein said basic body has on its polymeric surface a layer containing the imidazole derivative as an active ingredient, which displays an antithrombogenic, antiproliferative, anti-inflammatory or antiadhesive effect, or a combination thereof.

METHOD FOR INHIBITING PLATELET INTERACTION WITH BIOMATERIAL SURFACES

A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma. 125-. (cancelled)26. A medical device comprising:a biomaterial surface; anda layer of proteinaceous material adhered to the biomaterial surface, the proteinaceous material configured to exhibit at least one anti-thrombogenic property at the biomaterial surface following placement of the biomaterial surface within a human body, wherein the biomaterial surface is exposed to an electrical energy in the presence of a proteinaceous fluid to cause proteinaceous material to adhere to the biomaterial surface prior to placement of the biomaterial surface within the human body.27. The medical device of claim 26 , wherein the biomaterial surface has an electrical resistivity of less than about 5 ohms.28. The medical device of claim 26 , wherein the biomaterial surface is selected from the group consisting of pyrolytic carbon claim 26 , titanium claim 26 , nitinol claim 26 , stainless steel claim 26 , platinum claim 26 , and iridium.29. The medical device of claim 26 , wherein the electrical energy exposure is effected through direct electrical contact between an electrical energy source and the biomaterial surface.30. The medical device of claim 26 , wherein the proteinaceous material comprises conformationally altered fibrinogen.31. The medical device of claim 26 , wherein the proteinaceous material comprises albumin.32. The medical device of claim 26 , wherein the proteinaceous material comprises albumin and fibrinogen.33. The medical device of claim 26 , wherein the proteinaceous fluid is selected from the group consisting of blood claim 26 , plasma claim 26 , blood serum claim 26 , a fluid comprising a blood protein claim 26 , a fluid comprising albumin claim 26 , and a fluid comprising fibrinogen.34. The ...

BIOLOGICAL COMPONENT ADHESION-SUPPRESSING MATERIAL

A biological component adhesion-suppressing material includes a substrate provided with a functional layer having, fixed on a surface thereof that comes into contact with a biological component, a polymer including a saturated aliphatic monocarboxylic acid vinyl ester unit, wherein: when compositional analysis is performed on the surface of the functional layer using a TOF-SIMS device, the number of carbon atoms in an aliphatic chain representing an ion signal detected for saturated aliphatic carboxylic acid is 2-20; and an XPS measurement taken of the surface of the functional layer shows a peak derived from an ester group. 110.-. (canceled)11. A biological component adhesion-suppressing material comprising:a substrate having a functional layer with a polymer immobilized on a surface that is in contact with a biological component, the polymer containing a saturated aliphatic monocarboxylic acid vinyl ester unit,whereinthe number of carbon atoms in an aliphatic chain in a saturated aliphatic monocarboxylic acid ion signal detected in compositional analysis of the surface of the functional layer by a TOF-SIMS apparatus is 2 to 20, anda peak derived from an ester group is present in XPS measurement of the surface of the functional layer.12. The biological component adhesion-suppressing material according to claim 11 , wherein the saturated aliphatic monocarboxylic acid ion signal is derived from a saturated aliphatic monocarboxylic acid vinyl ester homopolymer or a copolymer containing a saturated aliphatic monocarboxylic acid vinyl ester claim 11 , and has antithrombogenicity.13. The biological component adhesion-suppressing material according to claim 11 , wherein the number of carbon atoms in an aliphatic chain in the saturated aliphatic monocarboxylic acid ion signal is 2 to 9.14. The biological component adhesion-suppressing material according to claim 11 , wherein claim 11 , in XPS measurement of the surface of the functional layer claim 11 , the area percentage ...

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Provided herein are compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and compositions. 2. The crystalline pharmaceutically acceptable salt of claim 1 , having an XRPD pattern with characteristic peaks between and including the following values of 2θ in degrees: 7.4 to 7.8 claim 1 , 13.3 to 13.7 claim 1 , 14.3 to 14.7 claim 1 , 15.2 to 15.6 claim 1 , 16.3 to 16.7 claim 1 , 17.2 to 17.6 claim 1 , 18.8 to 19.2 claim 1 , 20.2 to 20.6 claim 1 , 23.5 to 23.9 claim 1 , and 26.7 to 27.1.3. The crystalline pharmaceutically acceptable salt of claim 1 , having an XRPD pattern with characteristic peaks at the following values of 2θ in degrees: 7.6 claim 1 , 13.5 claim 1 , 14.5 claim 1 , 15.4 claim 1 , 16.5 claim 1 ,17. 4 claim 1 , 19.0 claim 1 , 20.4 claim 1 , 23.7 claim 1 , and 26.9.4. The crystalline pharmaceutically acceptable salt of claim 1 , having an XRPD pattern with characteristic peaks between and including the following values of 2θ in degrees: 7.4 to 7.8 claim 1 , 14.3 to 14.7 claim 1 , 16.3 to 16.7 claim 1 , 18.8 to 19.2 claim 1 , and 20.2 to 20.6.5. The crystalline pharmaceutically acceptable salt of claim 1 , having an XRPD pattern with characteristic peaks at the following values of 2θ in degrees: 7.6 claim 1 , 14.5 claim 1 , 16.5 claim 1 , 19.0 claim 1 , and 20.4.6. The crystalline pharmaceutically acceptable salt of claim 1 , having an XRPD pattern substantially as depicted in .7. The crystalline pharmaceutically acceptable salt of claim 1 , having an XRPD pattern substantially as depicted in .8. The crystalline pharmaceutically acceptable salt of claim 1 , wherein the crystalline pharmaceutically acceptable salt melts at a Tfrom about 178° C. to about 192° C. as determined by DSC at a ramp rate of 10° C./min.9. The crystalline pharmaceutically acceptable salt of claim 1 , having a DSC thermogram substantially as depicted in .11. The amorphous pharmaceutically acceptable salt of claim 10 , having an ...

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of making these compounds or pharmaceutically acceptable salts thereof and compositions and methods of use thereof. 2. The process of claim 1 , wherein the salt of Formula (II) is dissolved in an aprotic solvent.3. The process of or claim 1 , wherein the solvent comprises (e.g. claim 1 , consists of or consists essentially of) acetonitrile.4. The process of any one of to claim 1 , wherein the hydrogen chloride is added to the first solution by bubbling HCl gas into the first solution or by adding a second solution comprising HCl (e.g. claim 1 , an ethereal hydrochloric acid solution) to the first solution.5. The process of any one of to claim 1 , wherein the starting quantity of the salt of Formula (II) or solvate (e.g. claim 1 , a hydrate) thereof is greater than or equal to 500 grams.6. The process of any one of to claim 1 , wherein the starting quantity of the salt of Formula (II) or solvate (e.g. claim 1 , a hydrate) thereof is greater than or equal to 1 kilogram.7. The process of any one of to claim 1 , wherein the process produces over 300 grams (e.g. claim 1 , over about 350 grams (e.g. claim 1 , about 368 grams)) of pharmaceutically acceptable salt of Formula (I) or solvate (e.g. claim 1 , a hydrate) thereof.8. The process of any one of to claim 1 , wherein the process produces the pharmaceutically acceptable salt of Formula (I) or solvate (e.g. claim 1 , a hydrate) thereof in a yield greater than about 50% (e.g. claim 1 , in about 55% yield).9. The process of any one of to claim 1 , wherein the process produces the pharmaceutically acceptable salt of Formula (I) or solvate (e.g. claim 1 , a hydrate) thereof in a yield greater than about 75%.10. The process of any one of to claim 1 , wherein the process produces the pharmaceutically acceptable salt of Formula (I) or ...

BIORESORBABLE SCAFFOLD FOR NEUROLOGIC DRUG DELIVERY

Bioresorbable scaffolds and methods of treatment with such scaffolds for neurologic disorders including Parkinson's disease, Huntington's disease, Alzheimer's disease, and brain neoplasms are disclosed. The bioresorbable scaffold includes a bioresorbable body and an active agent or drug associated with the body for treating or ameliorating the neurological disorder. The bioresorbable scaffold is implanted in the neurological vasculature brain or brain tissue to provide localized delivery of the drug or active agent. Embodiments of the invention include scaffolds that are partially bioresorbable or completely bioresorbable. 1. An implantable bioresorbable scaffold for delivering a drug for treating a neurological disease in the central nerve system , comprising:a bioresorbable body; andan active agent associated with the bioresorbable body,wherein when the scaffold is implanted in a patient, the active agent, upon coming into contact with a protein that causes the neurological disease, the active agent renders the protein nonpathogenic.2. The scaffold of claim 1 , wherein the bioresorbable body completely resorbs upon completion of active agent delivery.3. The scaffold of claim 1 , wherein the active agent is a protease that renders the protein nonpathogenic by cleaving the protein.4. The scaffold of claim 1 , wherein the protease is a glutamic proteases found in filamentous fungi claim 1 , the glutamic proteases selected from the group consisting of A4 family of aspatic endopeptidases and Eqolisins.5. The scaffold of claim 1 , wherein the neurological disease is Huntington's or Parkinson's disease and the protein is polyglutamine.6. The scaffold of claim 1 , wherein the active agent is a glutamic protease7. The scaffold of claim 1 , wherein the active agent is a caspace claim 1 , calpain inhibitor claim 1 , or an inhibitor of β-secretase.8. The scaffold of claim 1 , wherein the active agent is immobilized on the scaffold such that the active agent cannot be released ...

FACTOR XII INHIBITORS FOR THE ADMINISTRATION WITH MEDICAL PROCEDURES COMPRISING CONTACT WITH ARTIFICIAL SURFACES

An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure. 120-. (canceled)21. A method of preventing or reducing a risk of thrombi formation or stabilization of formed thrombi in a human or animal subject during and/or after a medical procedure , comprising(A) administering to the subject an inhibitor of FXII/FXIIa before and/or during and/or after the medical procedure in an amount sufficient to prevent or reduce the risk of thrombi formation or stabilization during and/or after the medical procedure, and [{'sup': '2', '(i) is exposed to at least 80% of the blood volume of the subject and the artificial surface is at least 0.2 m,'}, '(ii) is a container for collection of blood outside the body of the subject, and/or', '(iii) is a stent, valve, intraluminal catheter, or a system for internal assisted pumping of blood., '(B) contacting blood of the subject with an artificial surface, wherein the artificial surface'}22. The method of claim 21 , wherein the subject does not have an increased bleeding risk after administering the inhibitor of FXII/FXIIa claim 21 , as determineda) via the ear or finger tip bleeding time method according to Duke and wherein said ear or finger tip bleeding time is not longer than 10 minutes,b) according to the method of Ivy and wherein the bleeding time is not longer than 10 minutes, and/orc) according to the method of Marx and wherein the bleeding time is not longer than 4 minutes.23. The method of claim 21 , wherein the medical procedure comprises one or more ofi) a cardiopulmonary bypass,ii) oxygenation and pumping of blood via extracorporeal membrane oxygenation,iii) assisted pumping of blood (internal or external),iv) dialysis ...

SORTASE-CATALYZED IMMOBILIZATION, RELEASE, AND REPLACEMENT OF FUNCTIONAL MOLECULES ON SOLID SURFACES

Compositions, reagents, kits, and methods for the reversible, covalent conjugation of functional molecules to engineered surfaces, e.g., surfaces of biomedical devices or used in analytical assays or industrial catalysis, are provided. The compositions, reagents, kits, and methods provided herein allow for the attachment, release, and replacement of functional molecules to and from engineered surfaces in vitro, in situ, and in vivo. Implantable vascular grafts, stents, catheters, and other medical devices with immobilized thrombomodulin-coated surfaces are provided. These molecules can be released from the device surface and replaced with fresh thrombomodulin via systemic administration of the respective reactants and without the need to remove the device. 1. A composition comprising ,an engineered solid support, anda first sortase recognition motif conjugated to the surface of the solid support.2. The composition of claim 1 , wherein the solid support comprises a polymer or copolymer.3. (canceled)4. The composition of claim 2 , wherein the polymer or co-polymer is chosen from the group consisting of polyurethane polymers and copolymers thereof claim 2 , polyoxymethylene polymers and copolymers thereof claim 2 , polyamide polymers and copolymers thereof claim 2 , polyacrylamide polymers and copolymers thereof claim 2 , polyvinyl polymers and copolymers thereof claim 2 , styrene-ethylene-butylene copolymers claim 2 , styrene-isoprene copolymers claim 2 , polyether polymers and copolymers thereof claim 2 , polyolefin polymers and copolymers thereof claim 2 , polypropylene polymers and copolymers thereof claim 2 , polyethylene polymers and copolymers thereof claim 2 , polytetrafluoroethylene (PTFE) polymers and copolymers thereof claim 2 , polyoxypropylene polymers and copolymers thereof claim 2 , polyoxyethylene polymers and copolymers thereof claim 2 , polyanhydride polymers and copolymers thereof claim 2 , polyvinylalcohol polymers and copolymers thereof claim 2 , ...

Medical devices with reduced thrombogenicity

A plasma-activated coating (PAC) process covalently binds enzymes in their bioactive state, has low thrombogenicity and can be robustly applied to medical devices, resisting delamination when deployed in vivo. Applying this process to attachment of proteins such as enzymes that inhibit thrombosis and anticoagulants such as heparin or heparin fragments, one can produce medical devices and other materials for use in vascular applications having a number of benefits including covalent attachment, not requiring intermediate linkers or chemistry; substrate independent—works on polymers, metals, ceramics, 3D shapes like stents, valves, etc.; bioactivity is retained; surface may retain greater bioactivity over time in vivo; Simultaneously supports endothelialisation; can be stored for long periods, following freeze drying, and retains effectiveness when rehydrated and; surface is able to bind many fibrinolytic enzymes such as streptokinase, urokinase, tPA, plasmin).

ANTITHROMBOTIC MATERIAL

An antithrombogenic material includes a coating material containing: a polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine and diallyldimethylammonium chloride; and an anionic compound containing a sulfur atom and having anticoagulant activity; and a base material whose surface is coated with the coating material; wherein the polymer is covalently bound to the base material; and an abundance ratio of nitrogen atoms to an abundance of total atoms as measured by X-ray photoelectron spectroscopy (XPS) on a surface of the base material is 6.0 to 12.0 atomic percent. 113.-. (canceled)14. An antithrombogenic material comprising: a polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine and diallyldimethylammonium chloride; and', 'an anionic compound containing a sulfur atom and having anticoagulant activity; and, 'a coating material containinga base material whose surface is coated with said coating material;whereinsaid polymer is covalently bound to said base material; andan abundance ratio of nitrogen atoms to an abundance of total atoms as measured by X-ray photoelectron spectroscopy (XPS) on a surface of the base material is 6.0 to 12.0 atomic percent.15. The antithrombogenic material according to claim 14 , wherein the abundance ratio of sulfur atoms to the abundance of total atoms as measured by X-ray photoelectron spectroscopy (XPS) on the surface of the base material is 3.0 to 6.0 atomic percent.16. The antithrombogenic material according to claim 14 , wherein said polymer has a quaternary ammonium group.17. The antithrombogenic material according to claim 16 , wherein each carbon chain bound to the nitrogen atom in said quaternary ammonium group is constituted by an alkyl group claim 16 , and the carbon number per alkyl group is 1 to 12.18. The antithrombogenic ...

Catheter Locking Solution Having Antimicrobial and Anticoagulation Properties

The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine. 1. A catheter locking solution comprising:a local anesthetic comprising at least one of dibucaine and tetracaine having anticoagulant and antimicrobial activity to reduce microbial growth and coagulation in an implanted catheter.2. The catheter locking solution of claim 1 , wherein the local anesthetic comprises one or more of an amino amide claim 1 , an amino ester claim 1 , an aminoacylanilide claim 1 , an aminoalkyl benzoate claim 1 , an amino carbonate claim 1 , an N-phenylamidine compound claim 1 , an N-aminoalkyl amid claim 1 , an aminoketone claim 1 , and combinations thereof.3. The catheter locking solution of claim 1 , wherein the local anesthetic further comprises one or more of bupivacaine claim 1 , ropivacaine claim 1 , etidocaine claim 1 , lidocaine claim 1 , prilocaine claim 1 , procaine claim 1 , novocaine claim 1 , choloroprocaine claim 1 , propoxycaine claim 1 , chlorocaine claim 1 , mepivacaine claim 1 , xylocaine claim 1 , benzocaine claim 1 , chloroprocaine claim 1 , cyclomethycaine claim 1 , dimethocaine claim 1 , popoxycaine claim 1 , proparacaine claim 1 , articaine claim 1 , carticaine claim 1 , levobupivacaine claim 1 , piperocaine claim 1 , trimecaine claim 1 , hexylcaine claim 1 , benoxinate claim 1 , butucaine claim 1 , diperodon claim 1 , phenacaine claim 1 , falicaine claim 1 , dyclonine claim 1 , pramoxine claim 1 , dimethisoquien claim 1 , and combinations thereof.4. The catheter locking solution of claim 1 , wherein ...

GRAPHENE-BASED MOLECULAR/ENZYMATIC INTEGRATED CATALYSTS

Described here is a graphene-catalysts conjugate, comprising: a graphene support; a first catalyst conjugated to the graphene support; and a second catalyst conjugated to the graphene support, and the second catalyst is different from the first catalyst. In some embodiments, the first catalyst and the second catalyst correspond to a tandem catalytic system to drive a chemical transformation. 1. A graphene-catalysts conjugate , comprising:a graphene support;a first catalyst conjugated to the graphene support; anda second catalyst conjugated to the graphene support, and the second catalyst is different from the first catalyst.2. The graphene-catalysts conjugate of claim 1 , wherein the first catalyst and the second catalyst correspond to a tandem catalytic system to drive a chemical transformation.3. The graphene-catalysts conjugate of claim 1 , wherein the first catalyst is a molecular catalyst.4. The graphene-catalysts conjugate of claim 1 , wherein the first catalyst is an organometallic catalyst.5. The graphene-catalysts conjugate of claim 1 , wherein the first catalyst is a metalloporphyrin.6. The graphene-catalysts conjugate of claim 1 , wherein the first catalyst is hemin.7. The graphene-catalysts conjugate of claim 1 , wherein the first catalyst is conjugated to the graphene support through π-π interactions.8. The graphene-catalysts conjugate of claim 1 , wherein the second catalyst is an enzymatic catalyst.9. The graphene-catalysts conjugate of claim 1 , wherein the second catalyst is an oxido-reductase.10. The graphene-catalysts conjugate of claim 1 , wherein the second catalyst is glucose oxidase.11. A biocompatible film claim 1 , comprising:a polymer film; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a graphene-catalysts conjugate of embedded in the polymer film.'}12. A biomedical device claim 1 , comprising:a main body portion; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a surface coating on the main body portion, and the surface ...

COATINGS AND BIOMEDICAL IMPLANTS FORMED FROM KERATIN BIOMATERIALS

Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof. 113.-. (canceled)14. A method of producing a charged fraction of keratin , comprising:providing a keratin solution comprising acidic and/or basic keratins;separating fractions of said acidic and/or basic keratins from said keratin solution; andcollecting at least one of said fractions;to produce at least one charged fraction of keratin,wherein said keratin comprises kerateine.15. The method of claim 14 , wherein said keratin consists essentially of kerateine.16. The method of claim 14 , wherein said keratin consists essentially of alpha kerateine.17. The method of claim 14 , wherein said keratin consists essentially of gamma kerateine.1820.-. (canceled)21. The method of claim 14 , wherein said keratin consists essentially of kerateine claim 14 , and wherein said providing step is carried out by:reacting human hair with thioglycoic acid acid; andextracting kerateine with a solution comprising tris base;to provide a keratin solution consisting essentially of kerateine.22. The method of claim 21 , wherein said kerateine consists essentially of alpha kerateine claim 21 , and wherein said providing step further comprises the steps of:precipitating alpha kerateine from said keratin solution consisting essentially of kerateine by addition of mineral acid to a pH of approximately 4;separating the precipitated alpha kerateine from solution;collecting the precipitated alpha kerateine; andoptionally, re-dissolving the alpha kerateine at pH 9 and re-precipitating at pH 4 to further purify;to provide said kerateine consisting essentially of alpha kerateine.23. An implantable biomedical device comprising:a substrate and a keratin derivative on said substrate,wherein said keratin derivative is present in an ...

METHOD FOR PRODUCING MEDICAL DEVICE AND MEDICAL DEVICE

Provided is a method for preparing a medical device which has a surface lubricating layer on a surface of a substrate and the surface of which exhibits lubricity and antithrombotic qualities when being wet. The method includes forming a coating layer that contains a hydrophilic polymer having at least one reactive functional group selected from the group consisting of an epoxy group, an acid chloride group, and an aldehyde group, and then applying onto the coating layer an antithrombotic material solution that contains an antithrombotic material having a functional group capable of binding to the hydrophilic polymer to form the surface lubricating layer. The concentration of the antithrombotic material in the antithrombotic material solution is more than 0 and less than 0.1 wt %. 1. A method for producing a medical device comprised of a surface lubricating layer on a surface of a substrate , in which the surface lubricating layer exhibits lubricity and antithrombotic qualities when being wet , the method comprising:forming onto the substrate a coating layer that contains a hydrophilic polymer having at least one reactive functional group selected from the group consisting of an epoxy group, an acid chloride group, and an aldehyde group;applying onto the coating layer an antithrombotic material solution that contains an antithrombotic material having a functional group that binds to the hydrophilic polymer to form the surface lubricating layer;the antithrombotic material in the antithrombotic material solution being present in a concentration more than 0 wt % and less than 0.1 wt %.2. The method for producing a medical device according to claim 1 , wherein the antithrombotic material has a sulfonate group or a sulfate group.3. The method for producing a medical device according to claim 2 , wherein the antithrombotic material contains a repeating unit derived from a monomer selected from the group consisting of 2-(meth)acrylamido-2-methyl-propanesulfonic acid claim 2 ...

EMBOLIZATION WITH TRANSIENT MATERIALS

Use of embolic material that is biodegradable provides for embolizing a hypervascular vessel formed in response to chronic inflammation in a musculoskeletal vasculature or a vessel related to production of ghrelin. The embolic material is biodegradable within a predetermined period of time. Medical systems are configured for delivery of embolic material for embolizing the hypervascular vessel or the vessel related to production of ghrelin. 1. A method of embolizing a hypervascular vessel formed in response to chronic inflammation in a musculoskeletal vasculature , the method comprisingadvancing a catheter through a vasculature to a parent artery; andreleasing an embolic material from a distal end of the catheter into a hypervascular vessel, with the embolic material blocking blood flow in the hypervascular vessel;wherein the embolic material is biodegradable within a predetermined period of time.2. The method of wherein the period of time is from 15 minutes to 48 hours as measured by an in vitro test in a physiological fluid or simulated physiological fluid.3. The method of wherein the fluid contains an amount of amylase that is found in human saliva or in human blood.4. The method of wherein the embolic material comprises a plurality of particles.5. The method of wherein the particles are substantially spherical embolization beads.6. The method of wherein the particles are comprised of crosslinked starch.7. The method of wherein the particles consist essentially of starch.8. The method of wherein the particles comprise amylose.9. The method of wherein the particles are comprised of a hydrolytically degradable hydrogel.10. The method of wherein the embolic material comprises particles consisting of polymeric origin.11. The method of wherein the embolic material is further biodegradable to biocompatible residues.12. The method of wherein the embolic material is biodegradable by enzymatic action.13. The method of wherein the enzyme is amylase.14. The method of wherein ...

Biocompatibility of solid surfaces

An improved spacer material for improving the biocompatibility of a biomaterial and a method for making it in which a polyalkylimine is covalently attached to an aminated substrate and combined with a crosslinking agent which is at least difunctional in aldehyde groups. The polyalkylizine can be, for example, polyethyleneimine and the crosslinking agent can be, for example, glutaraldehyde. Preferably, the crosslinking agent is applied in dilute solution and at a pH suitable to accomplish light crosslinking of the polyalkylimine and also provide aldehyde linkages at the interface between the biomolecule and the spacer.

BIOMIMETIC NANOFIBER TISSUE SCAFFOLDS

A biomimetic tissue scaffold for repairing an elongated tissue in need of repair can comprise a plurality of coiled flexible polymeric ribbons having a surface on which is formed an array of nanofibers, the ribbons forming a tubular body defining a first open end in which a first end of the elongated tissue is receivable, a second open end in which a second end of the elongated tissue is receivable, and a lumen extending between the first and second open ends. 1. A tissue scaffold , comprising:a plurality of coiled flexible polymeric ribbons, each ribbon having a surface on which is formed an array of nanofibers; wherein:the ribbons are arranged as a plurality of layers of coiled flexible polymeric ribbons,each layer supports or is supported by an adjacent layer, andeach layer has a handedness which differs from that of each adjacent layer.2. The tissue scaffold of claim 1 , wherein the ribbons define a tubular body having a first open end claim 1 , a second open end claim 1 , and a lumen extending between the first and second open ends.35-. (canceled)6. The tissue scaffold of claim 2 , further comprising a plurality of pores extending from an exterior surface of the body to the lumen.7. The tissue scaffold of claim 6 , wherein the pores are at least partially defined by gaps between the ribbons forming adjacent layers.8. A method of repairing an elongate tissue structure in need of repair claim 6 , comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'providing a tissue scaffold of ;'}securing a first end of the elongate tissue structure in the first open end of the tissue scaffold; andsecuring a second end of the elongate tissue structure in the second open end of the tissue scaffold.912-. (canceled)13. A tissue scaffold claim 6 , comprising:a first layer comprising a first plurality of coiled flexible polymeric ribbons, each ribbon having a surface on which is formed a first array of nanofibers;a second layer comprising a second plurality of coiled ...

心血管移植片

【課題】血栓形成性が大幅に低下した心血管移植片を提供する。【解決手段】柔らかいブロックと共有結合した硬いブロックを有する超分子化合物の繊維状ネットワークで作られた内壁を備える管状構造を含み、前記硬いブロックは、２－ウレイド－４［１Ｈ］－ピリミジノン（ＵＰｙ）化合物を含み、前記繊維状ネットワークは、平均繊維径が１～１０μｍの繊維を有する生体吸収性の電界紡糸不織繊維ネットワークであり、前記管状構造は、２～８ｍｍの内径と、２００～９００μｍの壁厚を有し、前記繊維は、前記管状構造において長手方向の軸を中心とした周方向に、前記周方向の線形弾性剛性と前記周方向に垂直な方向の線形弾性剛性との比が１：２～２未満：１となるように整列していることを特徴とする心血管移植片を提供する。【選択図】図６

Method for manufacturing medical device and medical device

Surface coating method and coated device

A multi-step method of forming a coating on a substrate, such as a stent or graft, is disclosed. The steps of the method include treating the surface with a plasma formed at or near atmospheric pressure to form one or more active species on the surface until a desired surface density of the active species is formed, and exposing the treated surface to a selected gas or liquid under conditions effective to convert the active species to a stable functional group. The exposed surface surface may be contacted with a surface-modifying group under conditions effective to covalently attach the surface-modifying group to the functional group. Also disclosed is a substrate having a to bioactive/biocompatible coating and/or a drug-releasable coating prepared by the method.

Polymeric articles having enhanced antithrombogenic activity

Plastic articles having enhanced antithrombogenic activity due to the presence of hydrophobic materials attached to amine compounds bonded on the surface of the plastic which repel bonded antithrom bogenic agents outwardly from the plastic surface, making them more readily available to the blood for subsequent thrombus inhibition.

Polymeric articles having enhanced antithrombogenic activity

Plastic articles having enhanced antithrombogenic activity due to the presence or hydrophobic materials attached to amine compounds bonded on the surface of the plastic which repel bonded antithrombogenic agents outwardly from the plastic surface, making them more readily available to the blood for subsequent thrombus inhibition.

Process for activating a polymer surface for covalent bonding for subsequent coating with heparin or the like

A dicarbonyl halide preferably a straight-chain-alkyl dicarbonyl dihalide, may be used to activate a substrate surface of preferably polyurethane or polyamide. Optionally, an amine-end blocked polymer may be reacted with the resulting activated surface by reaction between amine and dicarbonyl halide groups. Then, a material to be covalently bonded to said surface, such as heparin, may be reacted with free amine groups bonded to the surface by a carbodiimide process or the like.

Treatment of metallic surfaces using radiofrequency plasma deposition and chemical attachment of bioactive agents

A treatment for metallic surfaces and devices having metallic surfaces is described. A film of heptafluorobutylmethacrylate (HFBMA) is applied to a surface by radiofrequency (RF) plasma deposition and subsequently treated with a biologically active agent. A water vapor RF plasma treatment of the HFBMA coating provides reactive groups thereon which can covalently bond to the biologically active agent. Alternatively, a spacer group can be bonded to the activated HFBMA and the biologically active agent can then be bonded to the spacer group. Devices coated according to the invention possess enhanced biocompatibility and the HFBMA coatings are durable even under severe crimping and expansion conditions.

Method for imparting a bio-active coating

Disclosed are implantable medical devices with enhanced patency. Expanded polytetrafluoroethylene small caliber vascular grafts coated with polymer bound bio-active agents that exhibit enhanced patency are disclosed. The polymer bound bio-active agents can include anti-thrombogenic agents, antibiotics, antibacterial agents and antiviral agents. Methods of preparing same are also provided.

Compositions comprising oxidized cellulose

La presente invención proporciona composiciones comprendidas por celulosa oxidada (OC) y glicerol, con la relación de glicerol a OC de al menos aproximadamente 0,5:1 p/p de glicerol:OC y/o con la viscosidad de la composición al menos 10 % mayor que la del glicerol y menor que aproximadamente 2,6X109 cP, con el contenido 5 total de agua menor que aproximadamente 8 % p/p. Además, se proporciona un polvo para la prevención de adhesión comprendido de OC que tiene un contenido de carboxilo igual a menor que 18 %, caracterizado por una alta potencia de prevención de adhesión. Además, en la presente descripción se proporcionan usos de las composiciones como hemostáticos o como material 10 de prevención de adhesión, y métodos para la preparación de estas. The present invention provides compositions comprised of oxidized cellulose (OC) and glycerol, with the ratio of glycerol to OC of at least about 0.5: 1 w / w glycerol: OC and / or with the viscosity of the composition at least 10 % greater than glycerol and less than about 2.6X109 cP, with the total water content less than about 8% w / w. In addition, there is provided an adhesion prevention powder comprised of OC having a carboxyl content equal to less than 18%, characterized by high adhesion prevention power. In addition, the present disclosure provides uses of the compositions as hemostats or adhesion prevention material, and methods for the preparation thereof.

Mouldings with anticoagulant properties, their preparation and their use in the manufacturing of articles useful in medical fields

Molding materials having anticoagulant properties, their preparation and processing to give articles which are used in medical technology

A process for preparing molding materials having anticoagulant properties is described. Hydrophobic monomers are subjected to free-radical copolymerization with hydrophilic monomers having biospecifically active functions to produce the molding material. The molding material may then be shaped into articles which also have anticoagulant properties. These articles are extremely useful in, for example, medical applications in contact with a patient's biological fluid.

Materials for inhibiting adhesion of biocomponents

본 발명은 혈액 등과 접촉해도 혈소판이나 단백질의 부착을 억제 가능한 생체성분 부착 억제 재료를 제공하는 것을 목적으로 한다. 본 발명은 생체성분과 접촉하는 면에 포화 지방족 모노카르복실산 비닐에스테르 유닛을 함유하는 고분자가 고정된 기능층을 구비하는 기재로 이루어지고, 상기 기능층의 표면을 TOF-SIMS 장치로 조성 분석했을 때에 검출되는 포화 지방족 모노카르복실산의 이온 시그널의 지방족쇄 탄소수는 2∼20이며, 상기 기능층의 표면을 XPS 측정했을 때, 에스테르기 유래의 피크가 존재하는 생체성분 부착 억제 재료를 제공한다. An object of the present invention is to provide a material for inhibiting adhesion of biocomponents capable of inhibiting adhesion of platelets or proteins even in contact with blood or the like. The present invention is made of a substrate having a functional layer in which a polymer containing a saturated aliphatic monocarboxylic acid vinyl ester unit is fixed on a surface in contact with a biocomponent, and the surface of the functional layer is compositionally analyzed by a TOF-SIMS device. Provided is a material for inhibiting adhesion of biocomponents in which an ion signal of a saturated aliphatic monocarboxylic acid detected at the time of detection has an aliphatic chain carbon number of 2 to 20, and a peak derived from an ester group exists when the surface of the functional layer is measured by XPS.

A kind of hirudin is modified the preparation method of anticoagulant material

本发明涉及生物医用材料制备技术领域，具体涉及一种水蛭素改性抗凝血材料的制备方法。本发明将蜘蛛提取液、壳聚糖、桑黄多糖、葡萄糖等混合得到诱导液，将诱导液灌入猪小肠中，用宽体金线蛭吸吮诱导液增重，挤压出宽体金线蛭唾液得到纯化滤液，将丝素蛋白溶液、明胶液、盐酸四环素、纯化滤液混合、超滤得到浓缩液，最后经过冷冻干燥得到水蛭素改性抗凝血材料，明胶液中含有多种蛋白质和维生素，能对基体起到补充营养的作用，鱼鳞所含的不饱和脂肪酸，可以抑制血液中血蛋白的氧化，从而避免发生凝血效应，水蛭素能抗凝血、抗血栓形成，还能抑制凝血酶诱导的成纤维细胞的增殖和凝血酶对内皮细胞的刺激，应用前景广阔。

For the modification on fluid and the surface of solid repellency

本文公开了用于使表面改性以具有液体排斥性的制品、其制造方法以及用途。液体排斥表面包括表面，所述表面包括锚固层。在所述表面上形成固定分子锚固层的锚固层具有共价地连接至或吸附到所述表面和官能团上的头基。所述处理表面的官能团对涂覆至所述处理表面的润滑层具有亲和力。所述锚固层和可补充的润滑层通过非共价吸引力来保持在一起。总之，这些层形成排斥某些不混溶液体并防止所述不混溶液体内含有的组分的吸附、凝固以及表面污损的超排斥光滑表面。

Equipping vascular implants with an active principle

Procedure for fitting of vascular implant with an active principle comprises immersing the implant body in an alcoholic solution or an alcoholic solution with a light volatile solvent e.g. chloroform, and a member of gentamicin palmitate, gentamicin myristate, gentamicin laurate, tobramycin palmitate, tobramycin myristate, tobramycin laurate, amikacin palmitate, amikacin myristate, amikacin laurate, vancomycin palmitate or vancomycin myristate, or sprinkling the alcoholic solution on the implant body; and vaporizing the solvent, where the active principle is antithrombosis. An independent claim is included for a coated vascular implant, produced by the above procedure, a further medicament material is dispersed or suspended in the coating.

Equipping vascular implants with an active principle

Ein oder mehrere Stoffe der Gruppe bestehend aus Gentamicinpalmitat, Gentamicinmyristat, Gentamicinlaurat, Tobramycinpalmitat, Tobramycinmyristat, Tobramycinlaurat, Amikacinpalmitat, Amikacinmyristat, Amikacinlaurat, Vancomycinpalmitat, Vancomycinlaurat und Vancomycinmyristat sind zur antithrombogenen Ausstattung von Vaskulärimplantaten geeignet. Ein entsprechendes Verfahren zur Ausstattung von Vaskulärimplantaten mit einem antithrombogenen Wirkprinzip besteht insbesondere darin, dass der Implantatkörper A in eine alkoholische Lösung oder eine alkoholische Lösung mit einem leicht flüchtigen Lösungsmittel, wie z.B. Chloroform, eines Mitglieds der Gruppe des Gentamicinpalmitats, des Gentamicinmyristats, des Gentamicinlaurats, des Tobramycinpalmitats, des Tobramycinmyristats, des Tobramycinlaurats, des Amikacinpalmitats, des Amikacinmyristats, des Amikacinlaurats, des Vancomycinpalmitats und des Vanocmycinmyristats getaucht wird oder mit dieser Lösung besprüht wird, B und das alkoholische Lösungsmittel verdampft wird. One or more of the group consisting of gentamicin palmitate, gentamicin myristate, gentamicin laurate, tobramycin palmitate, tobramycin myristate, tobramycin laurate, amikacin palmitate, amikacin myristate, amikacin laurate, vancomycin palmitate, vancomycin laurate, and vancomycin myristate are useful in the antithrombogenic delivery of vascular grafts. A corresponding method for equipping vascular implants with an antithrombogenic active principle consists in particular in that the implant body A in an alcoholic solution or an alcoholic solution with a volatile solvent, such as chloroform, a member of the group of gentamicin palmitate, gentamicin myristate, gentamicin laurate, tobramycin palmitate, tobramycin myristate, tobramycin laurate, amikacin palmitate, amikacin myristate, amikacin laurate, vancomycin palmitate and vanocmycin myristate is dipped or sprayed with this solution, B and the alcoholic solvent is evaporated.

Coated vascular implants

Es werden beschichtete Vaskulärimplantate beschrieben, wobei die Schicht aus einem Stoff der Gruppe, bestehend aus Gentamicinpalmitat, Gentamicinmyristat, Gentamicinlaurat, Tobramycinpalmitat, Tobramycinmyristat, Tobramycinlaurat, Amikacinpalmitat, Amikacinmyristat, Amikacinlaurat, Vancomycinpalmitat, Vancomycinlaurat und Vancomycinmyristat, gebildet wird. Die Beschichtung ist antibiotisch und antithrombogen. In der Schicht kann ein weiterer synthetischer oder natürlicher Inhibitor der Blutgerinnung und/oder der Plättchenaggregation und/oder offenkettige oder cyclische DNA oder RNA oder synthetische DNA-Analoga und/oder ein oder mehrere Addukte, die aus offenkettiger oder cyclischer DNA oder RNA oder synthetischer Analoga der DNA und einem oder mehreren kationischen Antibiotika aufgebaut sind, teilweise oder vollständig eingeschlossen sein. Coated vascular implants are described, the layer being formed from a substance from the group consisting of gentamicin palmitate, gentamicin myristate, gentamicin laurate, tobramycin palmitate, tobramycin myristate, tobramycin laurate, amikacin palmitate, amikacin myristate, amikacin laurate, vancomymate comate, vancomate comatate, vancomate comatate, and The coating is antibiotic and antithrombogenic. A further synthetic or natural inhibitor of blood coagulation and / or platelet aggregation and / or open-chain or cyclic DNA or RNA or synthetic DNA analogues and / or one or more adducts which consist of open-chain or cyclic DNA or RNA or synthetic analogs can be present in the layer the DNA and one or more cationic antibiotics are constructed to be partially or completely included.

Antibiotic bonded prosthesis and process for producing same

There is disclosed an improved prosthesis coated, respectively, with an ionic surfactant, an antibiotic and/or antithrombiotic agent and treated with an immobilizing ionic exchange compound, to remove un-antibiotic bound ionic surfactant. The drug may be encapsulated within phospholipid vesicles which are bound to the prosthesis.

One-stage type coagulation preventing coating

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

The medical device and method that antithrombotic generates

本发明提供用于施加层到医疗装置和相关装置的方法。这些装置可包括支架。例如，所述装置可包括侧壁和所述侧壁中的多个孔隙，所述多个孔隙进行大小调整以在管状构件定位于血管中且邻近于动脉瘤时禁止血液通过所述侧壁流入动脉瘤中达到足以导致血栓形成并治愈所述动脉瘤的程度。所述装置可具有分布在所述装置的至少一部分上方的抗血栓产生的外层。

Medical material and medical device using the medical material

antithrombotic coating composition and antithrombotic coating method using the same

본 발명은 본 발명은 항혈전 코팅을 위한 조성물 및 이를 이용한 항혈전 코팅 방법에 관한 것으로 본 발명의 코팅액은 친수성이 강하고 생체적합성이 크기 때문에 얇고 유연한 코팅이 가능하며 동시에 항혈전 기능을 가지고 있다. 상기 코팅액은 혈관 카테터, 스텐트, 가이드 와이어 및 기타 침습성 의료 기기 코팅에 적합하다.

Immobilization method of bioactive molecules using polyphenoloxidase

본 발명은 폴리페놀산화효소를 이용한 생리활성 물질의 표면 고정화 방법에 관한 것으로, 보다 상세하게는 페놀 또는 카테콜 분자를 포함하는 생리활성 물질은 폴리페놀산화효소의 in situ 산화에 의하여 페놀 또는 카테콜 분자가 표면 접착력 갖는 도파 또는 도파 퀴논 형태로 변화되며, 이러한 도파 또는 도파 퀴논을 배위 결합을 통해 금속 또는 고분자 기재 표면에 단시간 내에 간단하면서도 안정적으로 고정화 시킬 수 있는 생리활성 물질의 표면 고정화 방법에 관한 것이다. 본 발명에 따른 생리활성 물질의 표면 고정화 방법은 의료용 금속 또는 고분자 소재 표면에 생리활성 물질을 간단한 방법으로 고정화할 수 있는 유용한 기술로서, 예를 들어, 정형외과 또는 치과용 임플란트 소재에 세포 부착 생리활성 물질을 쉽게 고정화하여 임플란트 후 빠른 골 조직 형성 유도에 효과적으로 사용될 수 있으며, 또한 스텐트 및 인공혈관과 같은 혈관계 의료용 소재에 항혈전성 생리활성 물질을 표면에 쉽게 고정화하여 혈액 적합성을 향상시키는 데에 효과적으로 사용될 수 있다. The present invention relates to a method of surface immobilization of a physiologically active substance using a polyphenol oxidase, and more particularly, a physiologically active substance containing a phenol or catechol molecule is phenol or catechol by in situ oxidation of a polyphenol oxidase. A molecule is changed into a waveguide or waveguide quinone form having surface adhesion, and relates to a surface immobilization method of a bioactive material that can be simply and stably immobilized on the surface of a metal or polymer substrate through coordination bonds in a short time. . The method of surface immobilization of a bioactive material according to the present invention is a useful technique for immobilizing a bioactive material on a surface of a medical metal or a polymer material by a simple method, for example, cell-attached bioactivity on an orthopedic or dental implant material. Easily immobilized material can be used to induce rapid bone tissue formation after implantation, and can also be effectively used to improve blood compatibility by easily immobilizing antithrombotic bioactive materials on surfaces in vascular medical materials such as stents and artificial blood vessels. Can be.

DEVICE FOR CAPTURE OF FREE CLOSES

1. Устройство для захвата свободных тромбов, содержащее обладающее антитромбиновой активностью соединение, иммобилизованное на его поверхностях.2. Устройство для захвата свободных тромбов по п.1, отличающееся тем, что конъюгат(ы) указанного содержащего обладающего антитромбиновой активностью соединения и макромолекулярного соединения иммобилизован(ы) на поверхности (поверхностях).3. Устройство для захвата свободных тромбов по п.2, отличающееся тем, что указанное макромолекулярное соединение составлено из элементов, происходящих по меньшей мере из одного типа мономеров, выбранных из группы, состоящей из этиленгликоля, винилацетата, винилпирролидона, пропиленгликоля, винилового спирта и силоксана.4. Устройство для захвата свободных тромбов по п.2, отличающееся тем, что указанное макромолекулярное соединение представляет собой один или несколько типов соединений, выбранных из группы, состоящей из модифицированных простым полиэфиром силиконов, сополимеров винилацетата и винилпирролидона и частично омыленных поливиниловых спиртов.5. Устройство для захвата свободных тромбов по п.4, отличающееся тем, что указанное макромолекулярное соединение представляет собой модифицированный простым полиэфиром аминосиликон.6. Устройство для захвата свободных тромбов по п.1, отличающееся тем, что указанное соединение, обладающее антитромбиновой активностью, представляет собой соединение, представленное следующей общей формулой (I).[где R1 представляет (2R,4R)-4-алкил-2-карбоксипиперидино группу, и Rпредставляет фенильную группу или остаток конденсированного полициклического соединения, причем остаток конденсированного по� РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК A61L 31/00 (13) 2014 102 166 A (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2014102166/15, 21.06.2012 (71) Заявитель(и): ИНОУЕ Кандзи (JP), ТОРЭЙ ИНДАСТРИЗ, ИНК. (JP) Приоритет(ы): (30) Конвенционный приоритет: 24.06.2011 JP 2011-140076 (85) Дата начала рассмотрения ...

Anti-thrombogenic medical devices and methods

의료 기기에 층들을 적용하는 방법 및 관련 기기가 제공된다. 이러한 기기는 스텐트를 포함한다. 예를 들어, 해당 기기는 측벽 및 해당 측벽 내에 복수개의 세공을 포함할 수 있고, 상기 복수개의 세공은 관형상 부재가 혈관 내에 그리고 동맥류에 인접하게 위치된 경우에 측벽을 통한 동맥류 내로의 혈류를 혈전증 및 동맥류의 치유를 초래하기에 충분한 정도로 저해하는 크기로 되어 있다. 상기 기기는 해당 기기의 적어도 일부 위에 분포된 항혈전형성 외층을 구비할 수 있다. A method of applying layers to a medical device and related devices are provided. Such a device includes a stent. For example, the device may include a plurality of pores in a sidewall and a corresponding sidewall, wherein the plurality of pores are configured such that blood flow into the aneurysm through the sidewall is reduced by thrombosis when the tubular member is positioned within and adjacent to the aneurysm. And to an extent sufficient to cause healing of the aneurysm. The device may have an anti-thrombogenic outer layer distributed over at least a portion of the device.

Coating composition for implanted medical device and method for coating of such device

FIELD: medicine, in particular coating composition for implanted medical device. SUBSTANCE: claimed composition contains at least one polymer and at least one biologically active substance, such as naphthazarin and/or naphthazarin derivative, in particular shikonin. Coated devices are useful as substituents of skin, bone, or cartilage and as prosthesis for vascular surgery. EFFECT: new coating composition for implanted medical devices. 22 cl, 1 dwg, 2 tbl, 1 ex ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß RU (19) (11) 2 308 295 (13) C2 (51) ÌÏÊ A61L 33/04 (2006.01) A61L 33/06 (2006.01) A61F 2/06 (2006.01) ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÎÏÈÑÀÍÈÅ ÈÇÎÁÐÅÒÅÍÈß Ê ÏÀÒÅÍÒÓ (72) Àâòîð(û): ÑÅÂÀÑÒÜßÍΠÂèêòîð (RU) (21), (22) Çà âêà: 2005104943/15, 19.07.2003 (24) Äàòà íà÷àëà îòñ÷åòà ñðîêà äåéñòâè ïàòåíòà: 19.07.2003 (73) Ïàòåíòîîáëàäàòåëü(è): ËÑ ÌÅÄÊÀÏ ÃÌÁÕ (DE) R U (30) Êîíâåíöèîííûé ïðèîðèòåò: 23.07.2002 (ïï.1-22) DE 10234398.5 (43) Äàòà ïóáëèêàöèè çà âêè: 10.07.2005 (45) Îïóáëèêîâàíî: 20.10.2007 Áþë. ¹ 29 2 3 0 8 2 9 5 (56) Ñïèñîê äîêóìåíòîâ, öèòèðîâàííûõ â îò÷åòå î ïîèñêå: RU 2089131 C1, 10.09.1997. ÅÐ 0496349 A1, 29.07.1992. RU 2071788 C1, 20.01.1997. RU 2012565 C1, 15.05.1994. (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 24.02.2005 Àäðåñ äë ïåðåïèñêè: 129010, Ìîñêâà, óë. Á.Ñïàññêà , 25, ñòð.3, ÎÎÎ "Þðèäè÷åñêà ôèðìà Ãîðîäèññêèé è Ïàðòíåðû", ïàò.ïîâ. Å.Å.Íàçèíîé, ðåã. ¹ 517 (54) ÊÎÌÏÎÇÈÖÈß ÄËß ÏÎÊÐÛÒÈß ÈÌÏËÀÍÒÈÐÓÅÌÎÃÎ ÌÅÄÈÖÈÍÑÊÎÃÎ ÓÑÒÐÎÉÑÒÂÀ È ÑÏÎÑÎÁ ÍÀÍÅÑÅÍÈß ÏÎÊÐÛÒÈß ÍÀ ÒÀÊÎÅ ÓÑÒÐÎÉÑÒÂÎ (57) Ðåôåðàò: Èçîáðåòåíèå îòíîñèòñ ê ìåäèöèíå, â ÷àñòíîñòè ê êîìïîçèöèè äë ïîêðûòè èìïëàíòèðóåìîãî ìåäèöèíñêîãî óñòðîéñòâà, êîòîðà ñîäåðæèò, ïî ìåíüøåé ìåðå, îäèí ïîëèìåð è, ïî ìåíüøåé ìåðå, îäíî áèîëîãè÷åñêè àêòèâíîå âåùåñòâî, íàïðèìåð íàôòàçàðèí è/èëè ïðîèçâîäíîå íàôòàçàðèíà, â ÷àñòíîñòè øèêîíèí. Óñòðîéñòâà ñ íàíåñåííûì ïîêðûòèåì èñïîëüçóþò â êà÷åñòâå çàìåíèòåëåé êîæè, êîñòåé èëè õð ùåé, è îíè èìåþò âàæíîå çíà÷åíèå â êà÷åñòâå ïðîòåçîâ äë ñîñóäèñòîé ...

Method for making an improved medical device and device so made

(57)【要約】 本発明は、改善された医療デバイスを提供する。本発明はまた、本発明の改善された医療デバイスを作製するための方法を提供する。詳細には、本発明は、医療デバイスを提供し、ここで、この医療デバイスは、本体部材；およびこの本体部材の少なくとも一部上のコーティングを備え、ここで、このコーティングは、第１の求電子的に活性な高分子量ポリアルキレンオキシドと第２の高分子量ポリオキシアルキレン誘導体とのインサイチュ縮合生成物を含む。

Nitric oxide-releasing polymers incorporating diazeniumdiolated silane derivatives

Biocompatible polymeric materials capable of providing in situ release of nitric oxide (NO) included diazeniumdiolated fumed silica as a filler in a multilayer polymer structure to release NO upon contact with water (blood). The blood-contacting polymer surface is preferably multi-layered so that the NO-releasing layer, containing the diazeniumdiolated fumed silica, is shielded from blood contact by one or more top (or base) coats. When in contact with blood, the NO released at the surface of the polymer prevents platelet activation and adhesion to the surface, thereby reducing platelet consumption, risk of thrombus formation and other clinical complications associated with interactions between blood and foreign materials.

TUBULAR FABRIC

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2019 113 522 A (51) МПК D03D 3/02 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2019113522, 29.09.2017 (71) Заявитель(и): ТОРЭЙ ИНДАСТРИЗ, ИНК. (JP) Приоритет(ы): (30) Конвенционный приоритет: 07.10.2016 JP 2016-199137; 30.11.2016 JP 2016-232444 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 07.05.2019 JP 2017/035530 (29.09.2017) (87) Публикация заявки PCT: A WO 2018/066476 (12.04.2018) Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, стр. 3, ООО "Юридическая фирма Городисский и Партнеры" R U (57) Формула изобретения 1. Трубчатая ткань, содержащая нити основы и нити утка, переплетенные друг с другом, где данная трубчатая ткань имеет внешний диаметр с вариацией в пределах 10% вдоль направления основы и удовлетворяет следующей формуле: (L2-L1)/L1≥0,1 в которой L1 обозначает измерительную длину трубчатой ткани, когда она сжата в направлении основы путем приложения нагрузки 0,01 сН/дтекс, определяемую после того, как внешний диаметр трубчатой ткани измеряют без приложения нагрузки к трубчатой ткани, чтобы определить максимальный внешний диаметр, и затем контрольные риски наносят вокруг внешней окружности трубчатой ткани, так что контрольные риски разделены пятикратной длиной максимального внешнего диаметра трубчатой ткани; и L2 обозначает измерительную длину трубчатой ткани, когда она вытянута в направлении основы путем приложения нагрузки 0,01 сН/дтекс, определяемую после того, как внешний диаметр трубчатой ткани измеряют без приложения нагрузки к трубчатой ткани, чтобы определить максимальный внешний диаметр, и затем контрольные риски наносят вокруг внешней окружности трубчатой ткани, так что контрольные риски разделены пятикратной длиной максимального внешнего диаметра Стр.: 1 A 2 0 1 9 1 1 3 5 2 2 (54) ТРУБЧАТАЯ ТКАНЬ 2 0 1 9 1 1 3 5 2 2 (86) Заявка PCT: R U (43) Дата публикации заявки: 09.11.2020 Бюл. № 31 (72) Автор(ы): ТАНАКА, Нобуаки (JP ...

Anti-thrombotic material

本发明的目的在于提供抗血栓性材料，其中将肝素或肝素的衍生物以外的抗血栓性化合物固定于基材上，防止了具有抗血栓性的化合物从基材上的溶出，可长期持续地发挥高的抗血栓性。本发明提供抗血栓性材料，其具有被覆材料、和表面用上述被覆材料被覆的基材，所述被覆材料含有：聚合物的骨架结构、4?（氨基甲基）苯甲脒或苯脒的骨架结构和甲氧基苯磺酰胺的骨架结构，上述被覆材料与上述基材共价结合，在该抗血栓性材料的表面，由X射线光电子能谱法（XPS）测定的、源自羰基的成分相对于C1s峰的全部成分的峰存在比率为1.0原子数%以上。

Patent FR2187849A1

Medical device polymer

A medical device and a method for its manufacture. The function of the medical device requires exposure of the device to the tissue of a patient. The device has a tissue-exposed portion constructed to release an agent that inhibits adverse reaction to the presence of the device defined by a polymeric surface-layer overlying in a supported manner a polymer defining a reservoir. The reservoir incorporates the agent in a manner that permits substantially free outward release of the agent from the reservoir and the overlying layer defines metering outward passages constructed to control the outward migration of the agent to enable prolonged release of the agent from the surface of the medical device to prevent the adverse reaction due to the presence of the device.

Cardiovascular graft

Catheter Locking Solution Having Antimicrobial and Anticoagulation Properties

The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.

Catheter locking solution having antimicrobial and anticoagulation properties

The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.

Catheter locking solution having antimicrobial and anticoagulation properties

The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.

Catheter locking solution having antimicrobial and anticoagulation properties

The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.

A catheter locking solution having antimicrobial and anticoagulation properties

The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.

Catheter Locking Solution Having Antimicrobial and Anticoagulation Properties

本发明包括了具有抗微生物和抗凝血性质的封管溶液，该封管溶液包含局部麻醉剂和稠化剂。本发明所述的局部麻醉剂可以是氨基酰胺；氨基酯；氨基酰基苯胺；氨基烷基苯甲酸酯；氨基碳酸酯；N-苯基脒化合物；N-氨基烷基酰胺；氨基酮或其组合和混合物。在本发明的一个具体实施方案中，所述的局部麻醉剂是丁卡因或地布卡因。

A catheter locking solution having antimicrobial and anticoagulation properties

本发明包括了具有抗微生物和抗凝血性质的封管溶液，该封管溶液包含局部麻醉剂和稠化剂。本发明所述的局部麻醉剂可以是氨基酰胺；氨基酯；氨基酰基苯胺；氨基烷基苯甲酸酯；氨基碳酸酯；N-苯基脒化合物；N-氨基烷基酰胺；氨基酮或其组合和混合物。在本发明的一个具体实施方案中，所述的局部麻醉剂是丁卡因或地布卡因。

COMPOSITION FOR COATING AN IMPLANTED MEDICAL DEVICE AND METHOD FOR COATING AN SUCH DEVICE

ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß (19) RU (51) ÌÏÊ 7 (11) 2005 104 943 (13) A A 61 L 33/04 ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÇÀßÂÊÀ ÍÀ ÈÇÎÁÐÅÒÅÍÈÅ (21), (22) Çà âêà: 2005104943/15, 19.07.2003 (71) Çà âèòåëü(è): ËÑ ÌÅÄÊÀÏ ÃÌÁÕ (DE) (30) Ïðèîðèòåò: 23.07.2002 DE 10234398.5 (72) Àâòîð(û): ÑÅÂÀÑÒÜßÍΠÂèêòîð (RU) (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 24.02.2005 (74) Ïàòåíòíûé ïîâåðåííûé: Åãîðîâà Ãàëèíà Áîðèñîâíà (86) Çà âêà PCT: EP 03/07913 (19.07.2003) Àäðåñ äë ïåðåïèñêè: 129010, Ìîñêâà, óë. Á.Ñïàññêà , 25, ñòð.3, ÎÎÎ "Þðèäè÷åñêà ôèðìà Ãîðîäèññêèé è Ïàðòíåðû", ïàò.ïîâ. Ã.Á. Åãîðîâîé (54) ÊÎÌÏÎÇÈÖÈß ÄËß ÏÎÊÐÛÒÈß ÈÌÏËÀÍÒÈÐÓÅÌÎÃÎ ÌÅÄÈÖÈÍÑÊÎÃÎ ÓÑÒÐÎÉÑÒÂÀ È R U Ôîðìóëà èçîáðåòåíè 1. Êîìïîçèöè äë ïîêðûòè èìïëàíòèðóåìîãî ìåäèöèíñêîãî óñòðîéñòâà, ãäå êîìïîçèöè äë ïîêðûòè ñîäåðæèò, ïî ìåíüøåé ìåðå, îäèí ïîëèìåð è, ïî ìåíüøåé ìåðå, îäíî áèîëîãè÷åñêè àêòèâíîå âåùåñòâî, îòëè÷àþùà ñ òåì, ÷òî áèîëîãè÷åñêè àêòèâíîå âåùåñòâî âûáðàíî èç ãðóïïû, ñîñòî ùåé èç íàôòàçàðèíà è ïðîèçâîäíîãî íàôòàçàðèíà. 2. Êîìïîçèöè äë ïîêðûòè ïî ï.1, îòëè÷àþùà ñ òåì, ÷òî ïðîèçâîäíîå íàôòàçàðèíà âûáðàíî èç ãðóïïû, ñîäåðæàùåé øèêîíèí, àëêàííèí, àðíåáèí. 3. Êîìïîçèöè äë ïîêðûòè ïî ï.2, îòëè÷àþùà ñ òåì, ÷òî ïðîèçâîäíîå íàôòàçàðèíà ïðåäñòàâë åò ñîáîé øèêîíèí. 4. Êîìïîçèöè äë ïîêðûòè ïî ï.1, îòëè÷àþùà ñ òåì, ÷òî, ïî ìåíüøåé ìåðå, îäíî áèîëîãè÷åñêè àêòèâíîå âåùåñòâî ïðèñóòñòâóåò â êîëè÷åñòâå îò 0,01 äî 5 ìàñ.%. 5. Êîìïîçèöè äë ïîêðûòè ïî ï.1, îòëè÷àþùà ñ òåì, ÷òî ïðîèçâîäíîå íàôòàçàðèíà âûáðàíî èç ãðóïïû, ñîäåðæàùåé øèêîíèí, àëêàííèí, àðíåáèí, è îíî ïðèñóòñòâóåò â êîëè÷åñòâå îò 0,01 äî 5 ìàñ.%. 6. Êîìïîçèöè äë ïîêðûòè ïî ï.1, îòëè÷àþùà ñ òåì, ÷òî, ïî ìåíüøåé ìåðå, îäíî áèîëîãè÷åñêè àêòèâíîå âåùåñòâî ïðèñóòñòâóåò â êîëè÷åñòâå, âûáðàííîì èç ãðóïïû, ñîäåðæàùåé 0,04 ìàñ.%, 0,05 ìàñ.%, 0,06 ìàñ.%, 0,07 ìàñ.%, 0,08 ìàñ.%, 0,09 ìàñ.%, 1 ìàñ.%. 7. Êîìïîçèöè äë ïîêðûòè ïî ï.1, îòëè÷àþùà ñ òåì, ÷òî óêàçàííûé ïîëèìåð âûáðàí èç ãðóïïû, ñîñòî ùåé èç áèîñîâìåñòèìîãî ïîëèìåðà, ...

Polymer compositions, coatings and devices, and methods of making and using the same

The disclosure provides for a biocompatible, thromboresistant coating including a chalcogenide compound that induces nitric oxide formation; and a biocompatible matrix incorporating the chalcogenide compound. Devices incorporating such coatings, and methods of making and using such coatings are also disclosed herein.

Medical device with biomolecule-coated surface graft matrix

A medical device having a surface graft matrix comprising carboxyl-functional groups located on the device, the surface graft matrix comprising an outer portion; and one or more biomolecules covalently coupled to the surface graft matrix, wherein a majority of the biomolecules are located in the outer portion of the surface graft matrix. The surface graft matrix can also be loaded with a pharmaceutical agent.

Process for coating stents

A process is provided for coating stents having a first and second surface with passages there between to avoid blockage and bridging of the passages. The process comprises contacting the stent with a liquid coating solution containing a film forming biocompatible polymer under conditions suitable to allow the film forming biocompatible polymer to coat at least one surface of the stent while maintaining a fluid flow through said passages sufficient prevent the film forming biocompatible polymer from substantially blocking said passages. Also described are stents coated by this process.

Medical device polymer

Thermoplastic polymer composition and medical devices made of the same

Thrombolytic treated intravascular medical device

An intravascular medical device having a structure shaped and sized for introduction into the vascular system of a patient including a base material and a coating of a thrombolytic agent on the base material. The thrombolytic agent advantageously dissolves or breaks up the formation of thrombus on the surface of the structure when placed in the vascular system of a patient. The intravascular medical device also includes a antithrombogenic agent for inhibiting the formation of thrombus on the surface of the medical device. The method of treating a medical device with a thrombolytic agent includes providing a base material for the medical device along with a thrombolytic agent. The base material is dipped into the thrombolytic agent and then removed to allow the thrombolytic agent to dry on the surface thereof. The dipping and drying steps are repeated to increase the concentration or quantity of the thrombolytic agent on the device.

Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups

A polybifunctional reagent is provided having a polymeric backbone, one or more pendent photoreactive moieties, and two or more pendent bioactive groups. The reagent can be activated to form a bulk material or can be brought into contact with the surface of a previously formed biomaterial and activated to form a coating. The pendent bioactive groups function by promoting the attachment of specific molecules or cells to the bulk material or coated surface. Bioactive groups can include proteins, peptides, carbohydrates, nucleic acids and other molecules that are capable of binding noncovalently to specific and complimentary portions of molecules or cells.

SUBSTRATE PROVIDED WITH A BLOOD COMPATIBLE SURFACE OBTAINED BY COUPLING WITH THE SURFACE OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE WITH AN INHIBITORY INFLUENCE ON THE FORMATION OF BLOOD CLOTS AND / OR CONTAINED FROM HARMFOLIC CIRCULARS.

Immobilization of Streptokinase

The invention comprises the construction of an implantable device consisting of a clot lysing inhibitor immobilized onto a biocompatible polymer, and the method of regulation of blood clotting time, the prevention of blood clot formation, and the hydrolysis of existing blood clots with the use of said device. A method is also disclosed to prevent the growth of fibrous connective tissue on prosthetic devices.

Non-thrombogenic intravascular time release catheter

An intravascular catheter comprising a cannula for insertion into a vascular system of a patient coated with hydrophilic polymer containing, in the polymer, an effective amount of polymyxin to prevent the growth of microorganisms is disclosed.

Multifunctional thrombo-resistant coatings and methods of manufacture

The present invention is directed to multifunctional thrombo-resistant coatings for use with biomedical devices and implants, such as a coating which includes a siloxane surface onto which a plurality of amine functional groups have been bonded. Covalently bonded to the amine functional groups are a plurality of poly(ethylene oxide) chains, such that a single poly(ethylene oxide) chain is bonded to a single amine functional group. A plurality of different bioactive molecules, designed to counteract specific blood-material incompatibility reactions, are covalently bonded to poly(ethylene oxide) chains, such that a single bioactive molecule is coupled to a single polyethylene oxide chain. The method of manufacturing the present invention include preparing a material having a siloxane surface onto which a plurality of amine functional groups have been bonded. This is achieved by plasma etching with ammonia gas or by plasma polymerization of a siloxane monomer in the presence of ammonia gas. The amine-containing siloxane surface is reacted with poly(ethylene oxide) chains terminated with functional groups capable of reacting with the amine groups on the siloxane surface. The material is then reacted with a plurality of different bioactive molecules which counteract the specific blood-material incompatibility reactions, such that a single bioactive molecule is coupled to a single poly(ethylene oxide) chain. The resulting siloxane surface contains a plurality of different bioactive molecules capable of reacting with blood components which come in proximity to the siloxane surface in order to resist blood-material incompatibility reactions.

Radiofrequency plasma biocompatibility treatment of inside surfaces of medical tubing and the like

Internal polymeric surfaces of medical devices are provided that have enhanced biocompatibility properties. The internal polymeric surface presents an anti-thrombogenic, fibrinolytic or thrombolytic interface with body fluids such as blood flowing through medical device tubing during implantation for medical procedures. The biocompatibility enhancing agent is secured to the polymeric substrate by a spacer molecule which is covalently bound to the internal polymeric surface which had been subjected to radiofrequency plasma treatment with a low pressure plasma medium of water vapor, oxygen or combination of water vapor and oxygen gas.

Coating for biomaterial that can be introduced into the bloodstream or into the tissue of the human body

Biocompatible medical article and method

A medical article having a metal or glass surface with the surface having an adherent coating of improved biocompatibility. The coating is made by first applying to the surface an silane compound having a pendant vinyl functionality such that the silane adheres to the surface and then, in a separate step, forming a graft polymer on the surface with applied vinylsilane such that the pendant vinyl functionality of the vinylsilane is incorporated into the graft polymer by covalent bonding with the polymer. Biomolecules may then be covalently attached to the base layer.

Vascular device and method for producing a vascular device

用于插入体内管腔(7)的血管装置(1)包含表面(111)，其中该表面(111)的至少一部分带有双电荷或更多电荷的离子(112)，使得在将血管装置(1)插入体内管腔(7)时离子(112)暴露于体液(71)。血管装置(1)能够减少其使用中的并发症，并且特别是用于改善期望的体内愈合并防止再狭窄。同时，它允许以相对较低的努力来制造并且便于处理。

A catheter locking solution having antimicrobial and anticoagulation properties

New biocompatible polymer systems carrying triflusal or htb

본 발명은 트리플루살 또는 HTB 를 수반하고, 아크릴계 또는 비닐계 단량체 A 를 중합하여 생성되는, 트리플루살 또는 HTB 를 수반하는 신규한 생체적합성 중합체 시스템에 관한 것으로, 트리플루살 또는 HTB 는 생체 내 가수분해성 공유 결합을 통해 상기 단량체 분자의 나머지 및 선택적으로 제 2 중합화가능 단량체 B 에 연결된다. 상기 신규한 중합체 시스템은 합성 바이오물질의 코팅물로서 유용하다. The present invention relates to a novel biocompatible polymer system involving triflusal or HTB, involving triflusal or HTB, and produced by polymerizing acrylic or vinyl monomers A. A bond is connected to the remainder of the monomer molecule and optionally to the second polymerizable monomer B. The novel polymer system is useful as a coating of synthetic biomaterials. 생체적합성 중합체, 트리플루살, HTB Biocompatible Polymer, Triflusal, HTB

Process for providing enzyme activity to a surface of an article and an article having enzyme activity on a surface thereof

A process for providing enzyme activity to the surface of an article is described, comprising forming a film on the surface of the article, said film comprising an acid anhydride group-containing polymer and a polyol, wherein the acid anhydride groups are partially reacted with the polyol, and thereafter reacting the unreacted acid anhydride groups with an enzyme. Such an article provided with enzyme activity on the surface can be used for the production of food, medicines, etc., and as a medical material eg. a blood purification adsorbent, an artificial organ (heart, lung, kidney), a surgical drain.

SUPPRESSING ADHESION OF BIOLOGICAL COMPONENT MATERIAL

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2019 104 422 A (51) МПК A61M 1/16 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2019104422, 28.07.2017 (71) Заявитель(и): ТОРЭЙ ИНДАСТРИЗ, ИНК. (JP) Приоритет(ы): (30) Конвенционный приоритет: 05.08.2016 JP 2016-154761 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 05.03.2019 R U (43) Дата публикации заявки: 07.09.2020 Бюл. № 25 (72) Автор(ы): УСИРО, Сугуру (JP), ХАЯСИ, Акихиро (JP), УЕНО, Йосиюки (JP) (86) Заявка PCT: (87) Публикация заявки PCT: WO 2018/025772 (08.02.2018) A Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, стр. 3, ООО "Юридическая фирма Городисский и Партнеры" R U (57) Формула изобретения 1. Подавляющий адгезию биологического компонента материал, который содержит: подложку, которая имеет функциональный слой с полимером, иммобилизованным на поверхности, который находится в контакте с биологическим компонентом, полимер содержит звено сложного винилового эфира насыщенной алифатической монокарбоновой кислоты, где число атомов углерода в алифатической цепи в сигнале иона насыщенной алифатической монокарбоновой кислоты, обнаруживаемом в анализе композиции поверхности функционального слоя с помощью аппарата TOF-SIMS, составляет от 2 до 20, и пик, характеризующий присутствие сложноэфирной группы, присутствует при XPS измерении поверхности функционального слоя. 2. Подавляющий адгезию биологического компонента материал по п. 1, в котором сигнал иона насыщенной алифатической монокарбоновой кислоты характеризует наличие гомополимера или сополимера сложного винилового эфира насыщенной алифатической монокарбоновой кислоты, содержащего сложный виниловый эфир насыщенной алифатической монокарбоновой кислоты, и обладающего антитромбогенностью. 3. Подавляющий адгезию биологического компонента материал по п. 1 или 2, в котором число атомов углерода в алифатической цепи в сигнале иона насыщенной Стр.: 1 A 2 0 1 9 1 0 4 4 2 2 (54) ПОДАВЛЯЮЩИЙ ...

Tubular fabric

涉及在流体、粉体移送用和金属线、线缆、电线管等线状物保护用软管、筒状过滤器、人工血管的基材等中有用的筒状织物。筒状织物，其是经纱和纬纱交错而织造的筒状织物，该筒状织物的经纱方向的外径之差为10%以内，所述筒状织物满足下式，(L2‑L1)/L1≥0.1 L1：以在不向上述筒状织物施加应力的状态下测定时的织物外径中的、该织物外径的最大值的5倍的距离在筒状织物的外周上画出标线，沿该筒状织物的经纱方向以0.01cN/dtex的应力压缩时的标线间距离。L2：以在不向上述筒状织物施加应力的状态下测定时的织物外径中的、该织物外径的最大值的5倍的距离在筒状织物的外周上画出标线，沿该筒状织物的经纱方向以0.01cN/dtex的应力伸长时的标线间距离。

Latency reactive polymers with biologically reactive components

RADIO FREQUENCY PLASMA TREATMENT OF MEDICAL DEVICES TO INCREASE THEIR BIOCOMPATIBILITY.

PROCESS FOR PREPARING BIOCOMPATIBLE PRODUCTS AND ARTICLES THUS OBTAINED

Procédé de préparation de produits biocompatibles et articles ainsi obtenus. Dans ce procédé on traite un produit polymère avec un agent d'hydrolyse à sa surface et on y lie de manière covalente un agent biologique, tel qu'un agent non-agglutinant les plaquettes. Utilisation de ce procédé pour fabriquer des articles prosthétiques biocompatibles. Process for preparing biocompatible products and articles thus obtained. In this process, a polymeric product is treated with a hydrolysis agent on its surface and a biological agent, such as a non-platelet-binding agent, is covalently linked thereto. Use of this process to manufacture biocompatible prosthetic articles.